Antibacterial therapy of endometritis after cesarian section: optimizing the dosing regime

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Purpose. To study the pharmacokinetics of β-lactam antibiotics in the development of endometritis after cesarean section to select the optimal dosage regimen.

Methods. A prospective, randomized, single-center study included 52 women in puerperas with endometritis after a caesarean section, divided into four groups. The patients of the first group (n = 17) received a course of ceftriaxone bolus in a single dose of 2.0 g (n = 10) and in the mode of prolonged perioperative infusion (n = 7). The patients of the second group (n = 10) received cefepim bolus at a dose of 2.0 g 2 times a day (n = 5) and in the extended infusion mode (n = 5). The patients of the third group (n = 14) received amoxicillin / clavulanic acid (Amoxiclav® 1000 mg + 200 mg) bolus at a dose of 1.0 g 3 times a day (n = 7) and in the extended infusion regimen (n = 7). The patients of the fourth group (n = 11) received ampicillin / sulbactam (Ampisid® 1000 mg + 500 mg) bolus at a dose of 1.0 g 4 times a day (n = 6) and in the extended infusion regimen (n = 5). We have compared the concentration of the studied antibiotics in the uterine cavity in the four groups using high performance liquid chromatography.

Results. The effective bactericidal concentration (C > 4×MIC) was not maintained throughout the entire dose interval in any of the treatment groups. The clinical efficacy and safety of the studied antibiotic regimens were similar. However, prolonged infusion of cefepime and aminopenicillins provided significantly higher concentrations in lochia.

Conclusion. Prolonged intravenous infusion of cefepime, ceftriaxone, amoxicillin / clavulanic acid and ampicillin / sulbactam in the treatment of endometritis after a caesarean section improves the pharmacokinetic / pharmacodynamic characteristics of these β-lactams in the uterine cavity, compared with the traditional bolus administration.

About the authors

Nikolay A. Korobkov

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: nikolai_korobkov@mail.ru
ORCID iD: 0000-0001-7279-2535

доцент кафедры акушерства и гинекологии

Russian Federation, Saint Petersburg

Natal'ya V. Bakulina

North-Western State Medical University named after I.I. Mechnikov

Email: nv_bakulina@mail.ru

д.м.н., профессор, зав. кафедрой внутренних болезней, клинической фармакологии и нефрологии 

Russian Federation, Saint Petersburg

M. A. Repina

North-Western State Medical University named after I.I. Mechnikov

Email: info@eco-vector.com

д.м.н., профессор

Russian Federation, Saint Petersburg

References

  1. Antimicrobial resistance. WHO. 2019. Available from: https://www.who.int/activities/optimizing-selection-and-use-of-antimicrobial-medicines.
  2. Avent, ML, Rogers BA. Optimising antimicrobial therapy through the use of Bayesian dosing programs. Int J Clin Pharm. 2019;41(5):1121–1130. https://doi.org/10.1007/s11096-019-00886-4.
  3. Brinkmann A, Rohr AC, Koberer A, et al. Adequate anti-infective treatment: Importance of individual dosing and application. Anaesthesist. 2018;67(6):461–476. (In German). https://doi.org/10.1007/s00101-018-0443-4.
  4. Maarbjerg SF, Thorsted A, Kristoffersson A, et al. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy? Pediatric blood & cancer. 2019;66(6):e27654. https://doi.org/10.1002/pbc.27654.
  5. Marsot A. Pharmacokinetic variability in pediatrics and intensive care: Toward a personalized dosing approach. J Pharm Pharm Sci. 2018;21(1):354–362. https://doi.org/10.18433/jpps30082.
  6. Септические осложнения в акушерстве: клинические рекомендации (протокол лечения) / Л.В. Адамян, Н.В. Артымук, Т.Е. Белокриницкая и др. – Москва, 2017. – 45 с. [Septicheskie oslozhneniya v хakusherstve: klinicheskie rekomendatsii (protokol lecheniya) / L.V. Adamyan, N.V. Artymuk, T.E. Belokrinitskaya, et al. Moskow; 2017. 45 p. (In Russ.)]
  7. Luo J, Liao J, Cai R, et al. Prolonged versus intermittent infusion of antibiotics in acute and severe infections: А meta-analysis. Arch Iran Med. 2019;22(10):612–626.
  8. Shiu J, Wang E, Tejani AM, Wasdell M. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev. 2013;28(3):CD008481. https://doi.org/10.1002/ 14651858.CD008481.pub2.
  9. Клинические рекомендации. Определение чувствительности микроорганизмов к антимикробным препаратам / Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии. 2014. C. 154. Режим доступа: http://metodichka.x-pdf.ru/15himiya/148495-1-metodicheskie-rekomendacii-utverzhdeni-rasshirennoe-soveschanie-mezhregionalnoy-associacii-klinicheskoy-mikrobiologii-anti.php. [Klinicheskie rekomendatsii. Opredelenie chuvstvitel’nosti mikroorganizmov k antimikrobnym preparatam. The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. 2014. P. 154. Available from: http://metodichka.x-pdf.ru/15himiya/148495-1-metodicheskie-rekomendacii-utverzhdeni-rasshirennoe-soveschanie-mezhregionalnoy-associacii-klinicheskoy-mikrobiologii-anti.php (In Russ.)]
  10. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: A review. Scand J Infect Dis Suppl. 1990;(74):63–70.
  11. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10. https://doi.org/10.1086/516284.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Concentrations of the investigated cephalosporins and inhibitor-protected aminopenicillins in lochia of parturient women with endometritis after a cesarean section at the end of the dosing interval for various modes of administration. * p < 0.05

Download (208KB)

Copyright (c) 2021 Korobkov N.A., Bakulina N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies